Stock Market Reviews

NBIX (Neurocrine Biosciences, Inc.) News

Get the latest news, insights, and market updates on NBIX (Neurocrine Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of clinical research on two FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors – INGREZZA® (valbenazine) capsules and deutetrabenazine – for the treatment of tardive dyskinesia. Among key insights, the review highlights the distinct profiles of VMAT2 inhibitors approved for tardive dysk
  Nov 20, 2025 - $NBIX
• Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck
  The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula
  Nov 19, 2025 - $NBIX
• Developmental and Epileptic Encephalopathies Market Research and Forecast Report 2025-2035: Gene Therapies and Rising Pediatric Prevalence Drive Growth
  The global developmental and epileptic encephalopathies market is set for substantial growth from 2024 to 2035, driven by the rising incidence among children and demand for effective treatments. Enhanced by advancements in gene therapy and neurostimulation, this market is shifting from mere symptom management to targeted, disease-modifying therapies. North America leads, bolstered by robust healthcare infrastructure and ongoing R&D investments. Key players such as Harmony Biosciences, Longboard
  Nov 19, 2025 - $NBIX
• Exploring 3 High Growth Tech Stocks in the US Market
  As the U.S. market experiences fluctuations with major indices like the Dow Jones and Nasdaq facing consecutive declines due to concerns over AI stock valuations, investors are closely monitoring high-growth sectors for potential opportunities. In such a dynamic environment, identifying tech stocks that demonstrate strong fundamentals and innovative capabilities can be crucial for navigating the evolving landscape of high-growth investments.
  Nov 18, 2025 - $NBIX
• Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
  Neurocrine Biosciences (NBIX) has seen meaningful movement over the past month, drawing investor attention to its latest performance metrics. Shares have advanced 7% in the past month and are up 17% over the past year, prompting a closer look at recent business fundamentals. See our latest analysis for Neurocrine Biosciences. The recent 1-month share price return of nearly 7% for Neurocrine Biosciences comes after a strong 1-year total shareholder return of 17%. This suggests growing...
  Nov 13, 2025 - $NBIX
• Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News
  If you have ever wondered whether Neurocrine Biosciences is currently trading for a bargain or riding high on hype, you are in the right place. The stock has made notable moves recently, rising 2.9% over the past week and climbing 7.8% in the last 30 days. This suggests shifting investor optimism and perhaps a reevaluation of risk and growth potential. Outside of earnings reports, recent headlines have highlighted Neurocrine’s progress with its clinical trials and an expanded partnership...
  Nov 12, 2025 - $NBIX
• Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
  Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
  Nov 11, 2025 - $NBIX
• Neurocrine Biosciences to Present at Upcoming Investor Conferences
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
  Nov 11, 2025 - $NBIX
• Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated.
  Nov 10, 2025 - $NBIX
• Neurocrine chalks up a depression drug failure
  Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero."
  Nov 10, 2025 - $NBIX